Sign in

CIK 0001157601 · Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
(267) 824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
Open-market buys, last 90 days
$35,023,032
in 1 filing
Open-market sales, last 90 days
$7,011,938
in 3 filings, $6.7M under 10b5-1 plans

Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. BAKER BROS. ADVISORS LP +$35.0M Director 1 filing
  2. Sibold William John −$6.2M President and CEO sold 6% of stake
  3. Kelley Shannon T −$773K General Counsel sold 14% of stake
Date Insider Transaction Shares Price Value Owned after
2026-02-23 Levy Richard S Director Option exercise +2,500 $7.36 $18K 27,697
2026-02-23 Levy Richard S Director Option exercise · Stock Option (Right to Buy) −2,500 0
2026-01-26 Levy Richard S Director Option exercise +4,000 $16.46 $66K 25,197
2026-01-26 Levy Richard S Director Option exercise · Stock Option (Right to Buy) −4,000 0
2026-01-26 Huntsman Carole Chief Commercial Officer Sale 10b5-1 −340 $492.42 $167K 9,692
2026-01-26 Huntsman Carole Chief Commercial Officer Sale 10b5-1 −570 $494.59 $282K 9,122
2026-01-26 Sibold William John President and CEO Sale −1,577 $492.42 $777K 148,497
2026-01-26 Taub Rebecca Director Sale −647 $492.42 $319K 452,704
2026-01-20 Kelley Shannon T General Counsel Sale 10b5-1 −263 $490.77 $129K 8,910
2026-01-20 Kelley Shannon T General Counsel Sale 10b5-1 −429 $501.40 $215K 8,481
2026-01-20 Taub Rebecca Director Sale −2,238 $490.77 $1.1M 453,351
2026-01-15 Thakkar Rita Chief Accounting Officer Grant or award +2,398 2,398
2026-01-15 Thakkar Rita Chief Accounting Officer Grant or award · Stock Option (Right to Buy) +1,826 1,826
2026-01-09 FRIEDMAN PAUL A Director Option exercise 10b5-1 +280 $15.80 $4K 187,444
2026-01-09 FRIEDMAN PAUL A Director Sale 10b5-1 −280 $551.24 $154K 187,164
2026-01-09 FRIEDMAN PAUL A Director Option exercise · Stock Option (Right to Buy) 10b5-1 −280 0
2026-01-09 FRIEDMAN PAUL A Director Option exercise 10b5-1 +24,520 $15.80 $387K 211,684
2026-01-09 FRIEDMAN PAUL A Director Sale 10b5-1 −1,480 $511.98 $758K 210,204
2026-01-09 FRIEDMAN PAUL A Director Sale 10b5-1 −1,094 $513.11 $561K 209,110
2026-01-09 FRIEDMAN PAUL A Director Sale 10b5-1 −1,345 $514.68 $692K 207,765

Page 6 of 82 · 1,629 trades